Details for Patent: 8,802,714

Which drugs does patent 8,802,714 protect, and when does it expire?

Patent 8,802,714 protects TPOXX and is included in two NDAs.

This patent has thirty-two patent family members in twelve countries.

Summary for Patent: 8,802,714

Title:	Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Abstract:	Methods of using di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus.
Inventor(s):	Jordan; Robert F. (Corvallis, OR), Bailey; Thomas R. (Phoenixville, PA), Rippin; Susan R. (Wilmington, DE), Dai; Dongcheng (Corvallis, OR)
Assignee:	Siga Technologies, Inc. (Corvallis, OR)
Application Number:	13/966,392
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 8,802,714

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Siga Technologies	TPOXX	tecovirimat	CAPSULE;ORAL	208627-001	Jul 13, 2018		RX	Yes	Yes						TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG
Siga Technologies	TPOXX	tecovirimat	SOLUTION;INTRAVENOUS	214518-001	May 18, 2022		RX	Yes	Yes						TPOXX IS INDICATED FOR THE TREATMENT OF HUMAN SMALLPOX DISEASE IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 3 KG

International Family Members for US Patent 8,802,714

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2004249250
Australia	2007351866
Canada	2529761
Canada	2685153